Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-analysis of the TWILIGHT and TICO Randomized Trials

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker's Bureau - AstraZenca; Abbott; Amgen; Boston Scientific Corporation